MCID: LYM012
MIFTS: 50

Lymphoplasmacytic Lymphoma

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Lymphoplasmacytic Lymphoma

MalaCards integrated aliases for Lymphoplasmacytic Lymphoma:

Name: Lymphoplasmacytic Lymphoma 12 37 15
Waldenstrom Macroglobulinemia 44 73
Malignant Lymphoma - Lymphoplasmacytic 73

Classifications:



Summaries for Lymphoplasmacytic Lymphoma

Disease Ontology : 12 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

MalaCards based summary : Lymphoplasmacytic Lymphoma, also known as waldenstrom macroglobulinemia, is related to waldenstrom macroglobulinemia and heavy chain disease. An important gene associated with Lymphoplasmacytic Lymphoma is PAX5 (Paired Box 5), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are cardiovascular system and cellular

Wikipedia : 76 Waldenström\'s macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is a type of cancer... more...

Related Diseases for Lymphoplasmacytic Lymphoma

Diseases related to Lymphoplasmacytic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 waldenstrom macroglobulinemia 32.6 CD40LG CXCR4 MYD88 PAX5
2 heavy chain disease 30.6 CD40LG MYD88
3 gamma heavy chain disease 30.4 CD40LG MYD88
4 macroglobulinemia 29.8 CD40LG CXCL12 CXCR4 MYD88 PAX5
5 cryoglobulinemia, familial mixed 29.4 CD40LG CD5
6 myeloma, multiple 29.4 CD40LG CXCL12 CXCR4
7 cryoglobulinemia 29.2 CD40LG CD5
8 cll/sll 28.7 CD5 PAX5 SLC35B2
9 leukemia, chronic lymphocytic 28.1 CD40LG CD5 CXCL12 CXCR4 PAX5
10 lymphoma, non-hodgkin, familial 28.0 CD40LG CD5 CXCL12 CXCR4 PAX5
11 lymphoplasmacytic lymphoma without igm production 12.1
12 waldenstroem's macroglobulinemia 11.7
13 lymphoma 10.8
14 monoclonal paraproteinemia 10.5 CD40LG MYD88
15 aids dementia complex 10.3 CXCL12 CXCR4
16 pleuropneumonia 10.3 CD40LG MYD88
17 b-cell lymphomas 10.3
18 avoidant personality disorder 10.2 CXCL12 CXCR4
19 diffuse large b-cell lymphoma 10.2
20 retinal hemangioblastoma 10.1 CXCL12 CXCR4
21 primary central nervous system lymphoma 10.1 CXCL12 MYD88 PAX5
22 intraocular lymphoma 10.1 CXCL12 CXCR4 PAX5
23 leukemia, chronic lymphocytic 2 10.1
24 leukemia 10.1
25 leukemia, b-cell, chronic 10.1
26 legionellosis 10.0 CD40LG MYD88
27 composite lymphoma 10.0 CD5 PAX5
28 human immunodeficiency virus infectious disease 10.0 CD40LG CXCL12 CXCR4
29 bladder lymphoma 10.0 CD5 PAX5
30 immune deficiency disease 10.0 CD40LG CXCL12 CXCR4
31 lymphoma, hodgkin, classic 10.0
32 histiocytosis 10.0
33 amyloidosis 10.0
34 whim syndrome 9.9 ACKR3 CXCL12 CXCR4
35 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9 CBFB MYH11
36 aplastic anemia 9.9
37 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.9
38 hepatitis 9.9
39 acquired von willebrand syndrome 9.9
40 hepatitis c 9.9
41 anemia, autoimmune hemolytic 9.8 CD40LG CD5
42 autoimmune disease of blood 9.8 CD40LG CD5
43 burkitt lymphoma 9.7
44 lymphoma, mucosa-associated lymphoid type 9.7
45 polycythemia vera 9.7
46 wiskott-aldrich syndrome 9.7
47 polyarteritis nodosa, childhood-onset 9.7
48 autoimmune lymphoproliferative syndrome, type v 9.7
49 follicular lymphoma 9.7
50 paroxysmal nocturnal hemoglobinuria 9.7

Graphical network of the top 20 diseases related to Lymphoplasmacytic Lymphoma:



Diseases related to Lymphoplasmacytic Lymphoma

Symptoms & Phenotypes for Lymphoplasmacytic Lymphoma

MGI Mouse Phenotypes related to Lymphoplasmacytic Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.98 ACKR3 CBFB CD40LG CXCL12 CXCR4 MYD88
2 cellular MP:0005384 9.95 CBFB CD40LG CXCL12 CXCR4 MYD88 MYH11
3 hematopoietic system MP:0005397 9.92 ACKR3 CBFB CD40LG CD5 CXCL12 CXCR4
4 immune system MP:0005387 9.86 ACKR3 CBFB CD40LG CD5 CXCL12 CXCR4
5 digestive/alimentary MP:0005381 9.77 ACKR3 CBFB CXCR4 MYD88 MYH11
6 mortality/aging MP:0010768 9.76 ACKR3 CBFB CD40LG CXCL12 CXCR4 MYD88
7 nervous system MP:0003631 9.56 MYD88 PAX5 ACKR3 CBFB CD40LG CD5
8 respiratory system MP:0005388 9.02 MYH11 ACKR3 CBFB CXCR4 MYD88

Drugs & Therapeutics for Lymphoplasmacytic Lymphoma

Drugs for Lymphoplasmacytic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
4
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
7
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 147-94-4 6253
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
25 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
26 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
35 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
45 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
47 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2
48 Methylprednisolone acetate Phase 4,Phase 2,Phase 1,Not Applicable
49 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 1,Not Applicable
50 Neuroprotective Agents Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 475)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
12 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
13 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
14 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
15 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
16 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
17 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
18 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
19 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
23 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
24 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
25 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
29 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
30 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
31 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
32 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
33 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
34 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
35 Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas Active, not recruiting NCT00877214 Phase 3 Rituximab;Rituximab / observation
36 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
37 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
38 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
39 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
40 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
41 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
42 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
43 Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Unknown status NCT00927797 Phase 2 Cyclophosphamide, Pentostatin, Rituximab
44 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
45 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
46 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
47 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
48 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
49 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
50 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa

Search NIH Clinical Center for Lymphoplasmacytic Lymphoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: waldenstrom macroglobulinemia

Genetic Tests for Lymphoplasmacytic Lymphoma

Anatomical Context for Lymphoplasmacytic Lymphoma

MalaCards organs/tissues related to Lymphoplasmacytic Lymphoma:

41
B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney, Nk Cells

Publications for Lymphoplasmacytic Lymphoma

Articles related to Lymphoplasmacytic Lymphoma:

(show top 50) (show all 166)
# Title Authors Year
1
Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation? ( 29868855 )
2018
2
Lung consolidation as a rare presentation of lymphoplasmacytic lymphoma with extramedullary WaldenstrAPm's macroglobulinemia. ( 29686791 )
2018
3
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. ( 29439670 )
2018
4
Pseudo liposarcomatous plasma cells in a patient with liposarcoma and lymphoplasmacytic lymphoma. ( 29531734 )
2018
5
Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. ( 28849690 )
2017
6
Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88(L265P) mutation. ( 28321094 )
2017
7
Ibrutinib therapy for lymphoplasmacytic lymphoma. ( 28543765 )
2017
8
Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21(st) century. ( 28280077 )
2017
9
Acquired von Willebrand Syndrome in IgM Monoclonal Gammopathy as the Presentation of Lymphoplasmacytic Lymphoma. ( 28695028 )
2017
10
Lymphoplasmacytic lymphoma presenting as retinal hemorrhage. ( 28084978 )
2017
11
Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia. ( 28286680 )
2017
12
Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis. ( 28381754 )
2017
13
Allogeneic Transplantation for Relapsed WaldenstrAPm Macroglobulinemia and Lymphoplasmacytic Lymphoma. ( 27789362 )
2017
14
Amyloid myopathy as the presenting feature of lymphoplasmacytic lymphoma. ( 28298851 )
2017
15
Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge. ( 28533926 )
2017
16
Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry. ( 28270351 )
2017
17
Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. ( 27329639 )
2016
18
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. ( 26980069 )
2016
19
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. ( 27840426 )
2016
20
Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected WaldenstrAPm macroglobulinemia/lymphoplasmacytic lymphoma. ( 27890075 )
2016
21
Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. ( 27722129 )
2016
22
Synchronous Microscopic Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Adrenal and Lymphoplasmacytic Lymphoma: De Novo Disease or Transformation? ( 27913781 )
2016
23
Coexistent adrenal diffuse large B cell lymphoma in a patient with WaldenstrAPm's macrogloblinemia/lymphoplasmacytic lymphoma. ( 27365139 )
2016
24
Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma. ( 26878134 )
2016
25
An uncommon case of lymphoplasmacytic lymphoma in cerebellopontine angle region: Case report with a literature review. ( 27559959 )
2016
26
MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting. ( 26231802 )
2015
27
Clinicopathologic Features and Outcomes of Lymphoplasmacytic Lymphoma Patients with Monoclonal IgG or IgA Paraprotein Expression. ( 26421453 )
2015
28
Lymphoplasmacytic Lymphoma with IgA Paraproteinemia. ( 26299085 )
2015
29
Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature. ( 25972321 )
2015
30
Lymphoplasmacytic lymphoma with prominent mast cell infiltrates. ( 26668914 )
2015
31
Emerging therapeutic options for WaldenstrAPm macroglobulinemia/lymphoplasmacytic lymphoma. ( 26196236 )
2015
32
A Rare Case of WaldenstrAPm Macroglobulinemia/Lymphoplasmacytic Lymphoma with Light Chain Discrepancy between B Lymphocyte Population and Serum Paraprotein. ( 26586715 )
2015
33
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. ( 25819228 )
2015
34
Intravascular large B-cell lymphoma secondary to lymphoplasmacytic lymphoma: a case report and review of literature with clonality analysis. ( 26045864 )
2015
35
Lymphoplasmacytic lymphoma: What we need to know. ( 26374283 )
2015
36
A tale of the unexpected: Amyloidoma associated with intracerebral lymphoplasmacytic lymphoma. ( 26476773 )
2015
37
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. ( 24711662 )
2014
38
MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. ( 25216226 )
2014
39
IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house. ( 24408161 )
2014
40
Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/WaldenstrAPm macroglobulinaemia. ( 24528127 )
2014
41
Incidence of lymphoplasmacytic lymphoma/WaldenstrAPm's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. ( 23784625 )
2014
42
Nodal involvement of extranodal marginal zone lymphoma with extreme plasmacytic differentiation (Mott cell formation) simulating plasma cell neoplasm and lymphoplasmacytic lymphoma. ( 25548763 )
2014
43
MYD88 mutant lymphoplasmacytic lymphoma/WaldenstrAPm macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. ( 24828863 )
2014
44
Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma. ( 24842316 )
2014
45
Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. ( 25696843 )
2014
46
Elevated risk of venous but not arterial thrombosis in WaldenstrAPm macroglobulinemia/lymphoplasmacytic lymphoma. ( 25196979 )
2014
47
Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma. ( 24859878 )
2014
48
Lymphoplasmacytic lymphoma exposed by haemoptysis and acquired von Willebrand syndrome. ( 24469392 )
2014
49
BEAM-conditioned autologous SCT improves the quality of response in WaldenstrAPm's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience. ( 24887384 )
2014
50
A Man with Paraneoplastic Retinopathy plus Small Fiber Polyneuropathy Associated with WaldenstrAPm Macroglobulinemia (Lymphoplasmacytic Lymphoma): Insights into Mechanisms. ( 24654565 )
2014

Variations for Lymphoplasmacytic Lymphoma

Expression for Lymphoplasmacytic Lymphoma

Search GEO for disease gene expression data for Lymphoplasmacytic Lymphoma.

Pathways for Lymphoplasmacytic Lymphoma

Pathways related to Lymphoplasmacytic Lymphoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.87 CD40LG CXCL12 CXCR4 MYD88 PAX5
2
Show member pathways
11.5 ACKR3 CXCL12 CXCR4
3 11.31 CD40LG CXCL12 MYD88
4 11.09 CD40LG MYD88
5 11.05 CXCL12 CXCR4
6 10.81 CXCL12 CXCR4
7 10.65 CD40LG CD5 CXCR4 PAX5

GO Terms for Lymphoplasmacytic Lymphoma

Cellular components related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 CD40LG CD5 CXCL12

Biological processes related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.5 ACKR3 CXCL12 CXCR4
2 response to virus GO:0009615 9.33 CXCL12 CXCR4 MYD88
3 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 9.26 ACKR3 CXCL12
4 regulation of B cell receptor signaling pathway GO:0050855 8.96 CBFB PAX5
5 chemokine-mediated signaling pathway GO:0070098 8.8 ACKR3 CXCL12 CXCR4

Molecular functions related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 scavenger receptor activity GO:0005044 9.16 ACKR3 CD5
2 coreceptor activity GO:0015026 8.96 ACKR3 CXCR4
3 C-X-C chemokine receptor activity GO:0016494 8.62 ACKR3 CXCR4

Sources for Lymphoplasmacytic Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....